SURPASS-ET Study Results Released: Ropeginterferon as Second-Line Therapy for High-Risk ET Achieves Dual Breakthrough in Efficacy and Safety丨EHA 2025

SURPASS-ET Study Results Released: Ropeginterferon as Second-Line Therapy for High-Risk ET Achieves Dual Breakthrough in Efficacy and Safety丨EHA 2025

2025.09.01
At the recently held International Congress of Hematology, treatment advances in the field of Myeloproliferative Neoplasms (MPN) have garnered significant attention. As a classic subtype of MPN, Essential Thrombocythemia (ET) has seen no substantial breakthroughs in its treatment over the past two decades. In a Plenary Presentation, Professor Harry Gill of the University of Hong Kong's School of Clinical Medicine, on behalf of collaborators from 59 research centers worldwide, announced the top-line data from the Phase III SURPASS-ET clinical study. The study confirms that the novel long-acting interferon, Ropeginterferon alfa-2b (hereinafter referred to as Ropeginterferon), is comprehensively superior to the conventional drug anagrelide in both efficacy and safety as a second-line therapy, bringing new hope to patients with high-risk ET.
Subverting Traditional Concepts: CLL Does Not Originate from a Single Clone; Multiple Independent Minor Clones Plant the “Seeds” Early On丨EHA 2025

Subverting Traditional Concepts: CLL Does Not Originate from a Single Clone; Multiple Independent Minor Clones Plant the “Seeds” Early On丨EHA 2025

2025.09.01
The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in person, gathering top experts and cutting-edge research from the global hematology community. At this conference, a revolutionary study on the origin of Chronic Lymphocytic Leukemia (CLL) attracted widespread attention. A research team from Spain, using multi-omics single-cell sequencing technologies, revealed that CLL does not, as traditionally believed, originate from a single clone. Instead, in some patients, multiple independent minor clones with the biological characteristics of CLL exist, having emerged and begun to evolve decades before the disease is diagnosed. This discovery not only profoundly reshapes our understanding of CLL pathogenesis but also provides a completely new theoretical basis for future early diagnosis and intervention strategies.
From Biological Mechanisms to Targeted Therapy: The Treatment of Immune Thrombocytopenia (ITP) Enters an Era of Precision丨EHA 2025

From Biological Mechanisms to Targeted Therapy: The Treatment of Immune Thrombocytopenia (ITP) Enters an Era of Precision丨EHA 2025

2025.08.30
The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in-person, gathering top experts and scholars from the global hematology community. During the highly anticipated Presidential Symposium, Professor Nicola Cooper, an immune-hematologist from Imperial College London, delivered a keynote speech on "Immune Thrombocytopenia (ITP): From Biology to Targeted Therapy." She systematically reviewed the century-long evolution of ITP from its initial recognition to modern treatment, and by focusing on cutting-edge research, she outlined a clear roadmap for the future of personalized, precision therapy.